Adjuvant trastuzumab emtansine halves the risk of invasive disease recurrence or death versus trastuzumab in patients with residual invasive human epidermal growth factor receptor 2-positive early breast cancer, researchers report.
Source:
N Engl J Med 2018; doi:10.1056/NEJMoa1814017 SABCS 2018; San Antonio, Texas, USA; 4–8 December
Carboplatin plus taxane neoadjuvant chemotherapy may be sufficient for women undergoing dual HER2 blockade for stage II–III HER2-positive breast cancer, findings from the TRAIN-2 study suggest.
Women who function better earlier in the day, so-called morning people, are less likely to develop breast cancer than those who consider themselves night owls, suggests a Mendelian randomization analysis.
In patients undergoing radical therapy for cancer, an 8-week run-in period of aspirin is acceptable and well tolerated, and could reduce the risk for nonadherence and participant attrition in adjuvant and prevention trials, say researchers.
Supplementing exemestane with the selective histone deacetylase inhibitor chidamide significantly prolongs the progression-free survival of women with hormone receptor-positive, HER2-negative advanced breast cancer, phase III trial findings indicate.
First-line treatment with the programmed cell death ligand 1 inhibitor atezolizumab plus nab-paclitaxel has achieved a significant progression-free survival advantage over taxane chemotherapy alone in patients with metastatic triple-negative breast cancer, research suggests.
Source:
N Engl J Med 2018; doi:10.1056/NEJMoa1809615 ESMO 2018; Munich, Germany; 19–23 October
Serum analysis suggests that within a year of beginning endocrine therapy after early breast cancer treatment, around one in six premenopausal women are no longer adherent to tamoxifen.
Source:
ESMO 2018 Congress; Munich, Germany: 19–23 October 2018 Ann Oncol 2018; 29: Supplement 8, abstract 185O_PR
Long-term use of adjuvant endocrine therapy by women with a history of nonmetastatic breast cancer can significantly alter their risk for some types of cardiovascular disease, a meta-analysis shows.
Two independent studies of older patients receiving initial chemotherapy for metastatic breast cancer or non-small-cell lung cancer have found that the risk for hospitalization or death may be predicted by the cytotoxic regimen used.
Source:
Cancer 2018; doi:10.1002/cncr.31760 JAMA Network Open 2018; 1: e183023
Lurbinectedin, a selective inhibitor of active transcription of protein-coding genes, has promising activity in patients with BRCA1/2-mutated metastatic breast cancer, phase II study data show.
Phase I trial findings suggest that patients with metastatic triple-negative breast cancer might benefit from treatment with the programmed cell death ligand 1 inhibitor atezolizumab.
The PARP inhibitor talazoparib extends progression-free survival and improves quality of life compared with standard chemotherapy, show findings from the phase III EMBRACA study of women with advanced breast cancer and a germline BRCA1/2 mutation.
Source:
N Engl J Med 2018; 379: 753–763 Ann Oncol 2018; doi:10.1093/annonc/mdy257
The focus this month is on early and late treatment effects in patients with breast cancer, including effects on endometrial cancer risk, cardiotoxicity, and skin toxicity.
Adding pertuzumab to trastuzumab plus an aromatase inhibitor may be effective for patients with human HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer, a phase II trial suggests.
The ESMO Translational Research and Precision Medicine Working Group has proposed a classification system that orders the value of molecular aberrations as oncologic clinical targets based on the supporting evidence available.
Canadian researchers have found that the use of radiotherapy after surgery for ductal carcinoma in situ leads to an improvement in breast cancer-specific survival, possibly due to its systemic effects.
The AVAST-M and E5103 trial results rule out the use of bevacizumab in the adjuvant setting in high-risk patients with cutaneous melanoma and HER2-negative breast cancer, respectively.
Source:
Ann Oncol 2018; doi:10.1093/annonc/mdy229 J Clin Oncol 2018; doi:10.1200/JCO.2018.79.2028